Propylthiouracil Dosing in Pregnant Women with Hyperthyroidism
For pregnant women with overt hyperthyroidism requiring treatment, initiate propylthiouracil at 300-400 mg daily in divided doses (typically every 8 hours), with the goal of maintaining maternal free T4 at or just above the upper limit of normal, then titrate to the lowest effective dose. 1, 2
Initial Dosing Strategy
The 2026 American Thyroid Association guidelines establish PTU as the preferred antithyroid drug before 16 weeks of pregnancy due to methimazole's teratogenic risks during first-trimester organogenesis 1.
Starting doses:
- Standard initial dose: 300 mg daily (divided into three doses, approximately every 8 hours) 2
- Severe hyperthyroidism or very large goiters: 400 mg daily 2
- Refractory cases: Up to 600-900 mg daily may be required initially 2, 3
The FDA label confirms these dosing parameters, with adults typically starting at 300 mg daily and occasionally requiring higher doses for severe disease 2.
Conversion from Methimazole
When switching from methimazole to PTU, use a 1:20 dose ratio (e.g., methimazole 5 mg once daily = PTU 50 mg twice daily) 1. This conversion should be considered if a woman presents on methimazole during early pregnancy, though the decision depends on timing of presentation and current methimazole dose.
Maintenance Dosing
Target maintenance dose: 100-150 mg daily 2. However, real-world data from Parkland Hospital showed that only 10% of compliant women achieved maintenance doses ≤150 mg by delivery, with most requiring higher doses to maintain euthyroidism 3. This highlights an important clinical reality: aggressive dosing may be necessary to prevent maternal and fetal complications, as uncontrolled thyrotoxicosis carries significant risks including stillbirth, heart failure, and preterm delivery 3.
Discontinuation Considerations
Low-dose PTU (100-200 mg/day) taken for >6 months pre-pregnancy may be discontinued upon pregnancy confirmation if the woman is euthyroid 1. This represents a conditional recommendation with low-level evidence, recognizing that 30-70% of women will relapse after discontinuation.
Monitoring and Titration
- Initial monitoring: TSH and free T4 every 2-4 weeks after achieving control 1
- When switching medications: Reassess thyroid function after 2 weeks, then every 2-4 weeks 4
- Therapeutic target: Maintain free T4 at or just above the upper limit of normal (or total T4 at 1.5 times upper limit) 4
Critical Timing Considerations After 16 Weeks
After 16 weeks gestation, it remains unclear whether PTU should be continued or switched to methimazole 1. The 2026 ATA guidelines acknowledge this uncertainty as a Good Practice Statement. The 2012 Endocrine Society guidelines recommended switching to methimazole after the first trimester due to PTU's rare but severe hepatotoxicity risk 4, but the most recent 2026 guidelines are more equivocal on this point.
Important Safety Caveats
PTU carries a risk of severe hepatotoxicity, including hepatic failure requiring transplantation or resulting in death 2. The FDA label emphasizes this risk, particularly in pediatric populations, though it can occur at any dose. Despite this, PTU remains preferred in the first trimester because methimazole's teratogenic risks (including aplasia cutis, choanal atresia, and esophageal atresia) outweigh PTU's hepatotoxicity risk during organogenesis 1, 5.
Monitor for hepatotoxicity symptoms: If patients develop tiredness, nausea, anorexia, fever, pharyngitis, or malaise, discontinue PTU immediately and obtain liver function tests 2. Consider monitoring liver function every 3-4 weeks in pregnant women on PTU 4.
Clinical Pitfalls to Avoid
Underdosing: The most significant risk is inadequate treatment. Uncontrolled maternal thyrotoxicosis causes heart failure, preeclampsia, stillbirth, and fetal thyrotoxicosis 3, 6. Aggressive therapy is appropriate, especially when pregnancy is advanced 3.
Late diagnosis: Women diagnosed during pregnancy (rather than before) have substantially worse outcomes, with delays in treatment correlating directly with adverse events 3. Early aggressive treatment is essential.
Excessive dose reduction: While the goal is the lowest effective dose, achieving textbook maintenance doses (100-150 mg) may not be realistic in many patients. Prioritize maternal euthyroidism over arbitrary dose targets 3.
Fetal hypothyroidism concerns: Research shows that even low doses of PTU (≤100 mg daily) can be associated with elevated fetal TSH in 21% of cases, while higher doses may actually result in normal fetal thyroid function 7. This counterintuitive finding suggests individualized dosing based on maternal thyroid status rather than uniformly low doses.
Alternative Approaches for Refractory Cases
Thyroidectomy may be indicated if: (1) severe adverse reaction to ATDs occurs, (2) persistently high doses are required (>450 mg/day PTU), or (3) patient is nonadherent with uncontrolled hyperthyroidism. Optimal timing is the second trimester 4.